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106One pitfall of reporting response is the phenomenon of “regres-
sion to the mean.” If enrollment requires a measurement below a
certain threshold, using a test with an element of variability, such as
LVEF, a measurement taken on 1 particular day might be lower
than the patients’ true average value. When the test is repeated (after
the intervention), the measurement is likely to have risen closer to
the patients’ true average. This may give the false impression of a
therapeutic improvement. Unless there is a control group for com-
parison, a reader may be misled into thinking that an intervention is
effective. Describing an intervention as “effective” should be reserved
for the ﬁndings of randomized controlled trials where there is a
signiﬁcant difference between the intervention and control groups.
The terms “outcome,” “response,” and “effect” are sometimes used
interchangeably in imaging research. We suggest simple deﬁnitions
to facilitate clear communication and avoid misinterpretation of
ﬁndings and even of study design.
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Qualitative Characterization of
Adipose Tissue by MDCT
We read with great interest the paper by Rosenquist et al. (1)
published recently in iJACC. The analysis performed on a large
cohort drawn from the Framingham Heart Study implies that lower
multidetector computed tomography (MDCT) attenuation of sub-
cutaneous adipose tissue and visceral adipose tissue is associated
with an adverse cardiometabolic risk proﬁle. We would like to reﬂect
on 2 aspects of the published data.
First, although imaging of adipose tissue by MDCT offers
relatively high resolution and reproducibility and has increasingly
been used as a research tool, the methodology of computed to-
mography fat volume calculations has never been validated. Mea-
surements are based on an arbitrary attenuation range (Hounsﬁeld
units), which is not set uniformly across the literature. Such
attenuation-based identiﬁcation may lead to the parts of adipose
tissue with the lowest and highest attenuation being left unac-
counted for. Furthermore, attenuation relies substantially on
computed tomography scan parameters, especially tube voltage (kV),
and also on patients’ characteristics. Tube voltage is often set
differently for lean and obese patients. All of these factors may lead
to a systematic bias in interpretation of a study such as that by
Rosenquist et al. (1). Scan parameters applied in the reported cohort
were not mentioned in the paper.Second, we know from basic research studies that adipose tissue may
display either an unfavorable or a favorable metabolic proﬁle (endocrine
and paracrine) depending on its location and metabolic status (2). As
an example, epicardial adipose tissue in patients with coronary artery
disease as opposed to patients without this disease showed intense
leukocyte inﬁltration, thickened interlobular septa, and increased neo-
vascularization (3). All of these elements are more radiodense than
lipid-laden adipocytes and thus may lead to higher, rather than lower,
MDCT attenuation of adipose tissue with a proinﬂammatory and
proatherosclerotic metabolic proﬁle. Results of our clinical study
corroborate this hypothesis (4). Furthermore, as noted by Rosenquist et
al. (1), lower attenuation of subcutaneous adipose tissue and visceral
adipose tissue was correlated with fat volume because larger, lipid-laden
adipocytes are less attenuating. In such circumstances, in a retrospec-
tive, cross-sectional study, it may be difﬁcult to distinguish the effects of
fat volume from those of its attenuation. Thus, it would be interesting
to see how the attenuation correlated with cardiometabolic risk factors
within subgroups with similar fat volumes.
To summarize, the study by Rosenquist et al. (1) adds signiﬁ-
cantly to the growing body of evidence on the research and clinical
role of MDCT-derived characterization of adipose tissue. However,
further research efforts to eliminate the aforementioned limitations
are warranted. Longitudinal designs, histopathology references,
methodological improvements, standardization of MDCT fat
measurements, and prospective methods of accounting for the
established confounding factors in adipose tissue attenuation and
volume measurements should be clariﬁed to further develop this
new, fascinating area of research.
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Myocardial Extracellular Volume
Measurement by Cardiac Magnetic
Resonance
Measuring myocardial extracellular volume (ECV) with cardiovascular
magnetic resonance is achieving increasing importance because it allows
quantiﬁcation of diffuse ﬁbrosis not detectable with conventional late
gadolinium enhancement techniques. However, the conditio sine qua
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107non to accurately measuremyocardial ECV consists of achievement of a
steady-state equilibrium of gadolinium-based contrast agent between
plasma and the cardiac interstitium. Currently, this requires a rather
complicated and time-consuming protocol, which hinders the large-
scale clinical application of this technique. In a recent issue of iJACC,
White et al. (1) wrote a seminal paper validating a bolus-only (pseudo-
equilibrium) technique to estimate the ECV in a wide range of cardiac
diseases, with different degrees of extracellular matrix expansion, by
comparing it against both a previously validated equilibrium (infusion)
technique and histology. In particular, they demonstrated that a
pseudo-equilibrium protocol (15 min after a 0.1 mmol/kg gadolinium
bolus) yielded ECV estimates comparable to those obtained with the
equilibrium protocol (0.1 mmol/kg bolus þ 0.011 mmol/kg/min
gadolinium infusion), even though the former overestimated myocar-
dial ECV in case of an important expansion of cardiac interstitium (i.e.,
ECV >0.4, as in the case of amyloid deposition or ﬁbrotic scars).
Moreover, both techniques showed very tight correlation with the
histologically determined collagen volume fraction.
Overall, the paper byWhite et al. (1) paves the way for clinical studies
on cardiac interstitium remodeling and for further methodological
studies exploring gadolinium contrast kinetics with particular regard to
diseases with extreme ECV expansion. In previous work, Flett et al. (2)
provided evidence on how the equilibrium can be reached with a
constant gadolinium infusion (0.1 mmol/kg þ 0.0011 mmol/kg/min
gadolinium) in patients with aortic stenosis or hypertrophic cardio-
myopathy. They acquired T1 values every 5 min and demonstrated that
the ECV remained constant over time and correlated with histology.
Another group (3) validated a different pseudo-equilibrium technique
(12 to 50 min after 0.2 mmol/kg gadolinium bolus) against a different
equilibrium technique (0.1 mmol/kg bolus þ 0.0017 mmol/kg/min
gadolinium infusion) in healthy volunteers, again by acquiringT1 values
every 5 min and demonstrating that ECV remained constant.
Conversely, little is known about gadolinium kinetics in cardiac
amyloidosis, which is characterized by marked interstitial expansion and
fast gadolinium accumulation but also very rapid gadolinium washout
from both the myocardium and the blood pool (4). In the current paper
(1), T1 acquisitions were performed only 15 min after bolus and during
infusion, with no serial T1 acquisitions to demonstrate a blood–
myocardium steady-state equilibrium. Moreover, the histological vali-
dation provided by the authors was limited to patients with aortic ste-
nosis undergoing valve replacement or patients with hypertrophic
cardiomyopathy undergoing septal myectomy (1,2). Histological vali-
dation of equilibrium or pseudo-equilibrium techniques is still lacking
for cardiac disease with ECV >0.4, such as in cardiac amyloidosis, in
which interstitial remodeling may be ascribed to disparate mechanisms
(including myocyte necrosis, amyloid deposition, and scarring).
Finally, we agree with the authors (1) that further technical devel-
opment is required before a bolus-only protocol for ECVmeasurement
becomes clinically available. This protocol should account for all
potentially relevant parameters (contrast delivery rate, dose, agent, and
acquisition timing) and be validated for diverse cardiac pathologies.
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REPLY : Myocardial Extracellular Volume
Measurement by Cardiac Magnetic Resonance
We thank Dr. Barison and colleagues for their interest in our
paper (1). Extracellular volume fraction (ECV) has promise as an
important future imaging biomarker but can be measured by a
number of different T1 mapping techniques (2,3). The primary
aim of our study was to support the concept that a sufﬁcient
dynamic (or “pseudo”) equilibrium exists with delay after a bolus
of contrast, such that an infusion-maintained steady state is not
necessary (1). By removing the need for this cumbersome, time-
consuming intervention (4), this method would expand the
clinical applicability of ECV quantiﬁcation into routine study.
We conﬁrmed that this approach is valid in the majority of
clinical patients who might be encountered in a clinic, but perhaps
not all.
The development of new imaging biomarkers requires multifac-
eted technical development, including correlation or “calibration”
with histology, clinical correlates (e.g., left atrial size), and hard
clinical outcomes. As Dr. Barison and colleagues rightly stress, no
histological correlations are yet available in “high ECV” diseases, in
particular, cardiac amyloidosis. Hopefully, this is within sight, but
histological quantiﬁcation has thus far proved challenging because
tissue stains have not adequately separated myocytes from amyloid
protein and ﬁbrosis.
Other methods, however, may be helpful. Dr. Barison and
colleagues point out that contrast behavior is abnormal in other
ways in amyloid. The behavior of contrast may reﬂect myocardial
wash-in/wash-out kinetics and total potential accumulation (vol-
ume of distribution), but other factors are at play. The decay curve
of gadolinium-diethylenetriaminepentaacetic acid in the blood is
multiexponential: ﬁrst dominated by redistribution in blood, then
by distribution with slow and fast exchange compartments in the
body, and later by renal elimination. These factors may be altered
in AL and ATTR amyloidosis. In AL amyloidosis in particular,
there may be large accumulations (in kilograms) of amyloid
deposits in the liver, spleen, tongue, and other soft tissues of the
body. Scrutiny of contrast behavior may therefore provide addi-
tional insights.
What is the correct ECV in amyloidosis? We found that the
ECV measured using the bolus-only method was consistently
higher than that determined by using the infusion method.
Although the infusion technique is theoretically superior, our global
